(Q52887713)

9 May 2018

title

Pembrolizumab for the treatment of non-small cell lung cancer. (English)

1 reference

9 May 2018

1 reference

Sung Hee Lim

1

1 reference

9 May 2018

Jong-Mu Sun

2

1 reference

9 May 2018

Se-Hoon Lee

3

1 reference

9 May 2018

Jin Seok Ahn

4

1 reference

9 May 2018

Keunchil Park

5

1 reference

9 May 2018

Myung-Ju Ahn

6

1 reference

9 May 2018

language of work or name

English

0 references

publication date

22 January 2016

1 reference

9 May 2018

Expert Opinion on Biological Therapy

published in

1 reference

9 May 2018

volume

16

1 reference

9 May 2018

issue

3

1 reference

9 May 2018

page(s)

397-406

1 reference

9 May 2018

Cancer immunotherapy comes of age

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Programmed death ligand-1 expression in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Mutational heterogeneity in cancer and the search for new cancer-associated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Mutational profiling of colorectal cancers with microsatellite instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1145652

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1002/J.1460-2075.1992.TB05481.X

Identifiers

DOI

10.1517/14712598.2016.1145652

1 reference

9 May 2018

1 reference

9 May 2018